Inventiva (NASDAQ:IVA) Now Covered by Analysts at Barclays

Investment analysts at Barclays assumed coverage on shares of Inventiva (NASDAQ:IVA) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $18.00 price target on the stock. Barclays‘s price target would indicate a potential upside of 163.54% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on IVA. HC Wainwright set a $24.00 price objective on shares of Inventiva and gave the stock a “buy” rating in a report on Wednesday. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price target on shares of Inventiva in a research note on Tuesday, September 30th. Guggenheim reduced their price objective on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Wolfe Research upgraded Inventiva to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Inventiva has an average rating of “Buy” and an average price target of $16.22.

Inventiva Stock Performance

Shares of IVA stock opened at $6.83 on Tuesday. The company’s fifty day moving average price is $4.96 and its 200-day moving average price is $4.77. Inventiva has a 12 month low of $2.18 and a 12 month high of $7.98.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in IVA. Wealth Enhancement Advisory Services LLC boosted its holdings in Inventiva by 54.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after purchasing an additional 5,843 shares during the last quarter. Creative Planning bought a new position in shares of Inventiva during the 2nd quarter valued at $32,000. Millennium Management LLC bought a new stake in shares of Inventiva in the third quarter worth $649,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Inventiva in the third quarter worth $116,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.